Organigram Reports Record Third Quarter Fiscal 2026 Results August 11, 2026 Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 2026 August 11, 2026 Recognition highlights the MultiBank Group Founder and Chairman’s leadership, global experience and contribution to the financial services industry
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares August 10, 2026 Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the [...]
Point2 Completes $136M Series B Funding with Arm, LB Investment, and Maverick Silicon August 10, 2026 New Funding Further Solidifies Point2’s e‑Tube Technology Platform as the Foundation for Next-Generation AI Data-Center Interconnect
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer August 10, 2026 Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management
The World’s Largest AI Companies Built Deployment Arms This Year. Harbor Built One for Law August 10, 2026 Harbor Deploy is the first AI deployment offering built exclusively for law firms and corporate legal departments, bringing the embedded-engineering model now reshaping enterprise AI to the industry where confidentiality, professional judgment, and duty to the client are non-negotiable.
AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium August 10, 2026 AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS, powered by Airspan’s MobileAccess 6000 Digital platform. Led and owned by AT&T as a neutral-host network, the new DAS is designed to deliver high-capacity, multi-operator [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results August 10, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for polycythemia vera (PV) and other blood disorders Presented follow-up data from the Phase 1 SANRECO trial [...]
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera August 9, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call [...]